288. Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details

Clinical trials : 206 / Drugs : 231 - (DrugBank : 28) / Drug target genes : 10 - Drug target pathways : 21

diseases per page:

Showing 1 to 10 of 206 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05582993 (ClinicalTrials.gov)	January 9, 2023	14/10/2022	A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand ...	A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophy ...	Von Willebrand Disease (VWD)	Biological: Recombinant von Willebrand Factor (rVWF);Biological: ADVATE	Takeda	NULL	Not yet recruiting	N/A	17 Years	All	24	Phase 3	NULL
2	NCT05500807 (ClinicalTrials.gov)	November 1, 2022	12/8/2022	Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A	Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A	Von Willebrand Disease, Type 3;Concomitant VWD and Hemophilia	Drug: Emicizumab	Bleeding and Clotting Disorders Institute Peoria, Illinois	Genentech, Inc.	Recruiting	2 Years	90 Years	All	40	Phase 1	United States
3	NCT05345197 (ClinicalTrials.gov)	August 31, 2022	18/4/2022	Emicizumab in Patients With Acquired Hemophilia A	Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Tria ...	Acquired Hemophilia A	Drug: emicizumab	University of Washington	Genentech, Inc.	Recruiting	18 Years	N/A	All	51	Phase 2	United States
4	NCT04580407 (ClinicalTrials.gov)	November 9, 2021	5/10/2020	Study of TAK-672 in Participants With Acquired Hemophilia A	A Phase 2/3, Open-Label, Non-controlled Study to Evaluate the Efficacy and Safety of B-Domain Delete ...	Acquired Hemophilia A	Biological: TAK-672	Takeda	NULL	Completed	18 Years	N/A	All	5	Phase 2/Phase 3	Japan
5	NCT04567511 (ClinicalTrials.gov)	September 1, 2021	29/7/2020	Hemlibra in Mild Hemophilia A	Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia ...	Factor VIII Deficiency, Congenital	Drug: Emicizumab	Indiana Hemophilia &Thrombosis Center, Inc.	Genentech, Inc.	Recruiting	5 Years	45 Years	Male	40	Phase 4	United States
6	NCT04953884 (ClinicalTrials.gov)	July 28, 2021	18/6/2021	Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 ...	Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in ...	Von Willebrand Disease	Drug: wilate	Octapharma	NULL	Recruiting	N/A	5 Years	All	12	Phase 3	United States;Belarus;Czechia;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine
7	EUCTR2019-004430-42-AT (EUCTR)	22/06/2021	22/04/2021	Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no fa ...	Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Tria ...	Acquired Hemophilia A(AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquir ...	Trade Name: Hemlibra ® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB	GWT-TUD GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	47	Phase 2	Austria;Germany
8	NCT04188639 (ClinicalTrials.gov)	March 23, 2021	4/12/2019	Emicizumab in Acquired Hemophilia A	Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Tria ...	Hemophilia A, Acquired	Drug: Emicizumab Injection	GWT-TUD GmbH	Hoffmann-La Roche;Hannover Medical School	Completed	18 Years	N/A	All	47	Phase 2	Austria;Germany
9	EUCTR2019-004430-42-DE (EUCTR)	25/01/2021	20/11/2020	Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no fa ...	Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Tria ...	Acquired Hemophilia A(AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquir ...	Trade Name: Hemlibra ® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB	GWT-TUD GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	47	Phase 2	Austria;Germany
10	NCT04119908 (ClinicalTrials.gov)	January 2021	7/10/2019	Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases	Interest of Sublingual Videomicroscopy for the Prediction of Bleeding in Von Willebrand Diseaseand O ...	Von Willebrand Diseases;Glanzmann Thrombasthenia	Device: Sublingual videomicroscopy;Biological: blood sample	University Hospital, Lille	NULL	Not yet recruiting	18 Years	N/A	All	400	N/A	NULL

First Previous1 2 3 4 5…21Next Last